Tranexamic Acid in Patients Undergoing Rhinoplasty: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Background: Rhinoplasty is one of the most popular aesthetic plastic surgeries worldwide. The effects of tranexamic acid (TXA) in patients undergoing rhinoplasty are still being studied to guide a better management. Methods: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) analyzing the effects of TXA in patients undergoing rhinoplasty. The outcomes evaluated were blood loss, postoperative edema, postoperative ecchymosis, surgery duration and surgeon satisfaction. Results: Eleven studies comprising 841 patients were included. Overall, TXA reduced total blood loss regardless of dose and administration route (MD = − 39.37 mL; 95% CI = − 62.70 to − 16.05 mL; p = 0.0009; I² = 92%), using intravenous 10 mg/kg of TXA preoperatively (MD = − 16.30 mL; 95% CI = − 29.49 to − 2.57 mL; p = 0.02; I² = 61%) and using 1 g of oral TXA preoperatively (MD = − 61.70 mL; 95% CI = − 83.02 to − 40.39 mL; p < 0.00001; I² = 0%). TXA also decreased edema (MD = − 0.78; 95% CI = − 1.28 to − 0.27 points; p = 0.003; I² = 80%) and ecchymosis (MD = − 1.13; 95% CI = − 1.99 to -0.28; p = 0.01; I² = 93%) on postoperative day one (POD 1). Surgeon satisfaction was increased (SMD = 1.55; 95% CI = 0.33 to 2.77; p = 0.01; I² = 95%). However, there was no difference in surgery duration (SMD = − 0.26; 95% CI = − 0.56 to 0.04; p = 0.09; I² = 36%). Conclusion: This study found a significant reduction in blood loss, periorbital edema and periorbital ecchymosis, along with an improvement in surgeon satisfaction. These results hold the potential to optimize the rhinoplasty management by plastic surgeons. Level of Evidence I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266. [ABSTRACT FROM AUTHOR]